Eha 2023 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eha 2023. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eha 2023 Today - Breaking & Trending Today

ICYMI: Highlights From EHA 2023

The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology. ....

Hans Scheurer , Workgroup Of European Cancer Patient Advocacy Networks , European Hematology Association , Hematology Association , Annual Meeting , Term Data Show , Show Differences , Treatment Patterns , Oncology Move Beyond , Usual Disease , European Cancer Patient Advocacy Networks , Breaking Abstracts Offer Sneak Peek , 2023 European Hematology Association Annual Meeting , Eha 2023 , Eha Annual Meeting 2023 , Eha 2023 News Coverage ,

Polatuzumab Vedotin Substitution in R-mini-CHOP Does Not Worsen High-Grade Toxicities in DLBCL

Using polatuzumab vedotin instead of vincristine in a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, and prednisone was not found to increase grade 3/4 hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated diffuse large B-cell lymphoma. ....

Comprehensive Geriatric , Diffuse Largeb Cell Lymphoma , Eha 2023 , Polatuzumab Vedotin Polivy , R Pola Mini Chp , Phase 3 Polar Bear Trial Nct04332822 ,

Daratumumab Ixazomib and Dexamethasone Produces Significant Responses in R/R Multiple Myeloma

The combination of daratumumab, ixazomib, and dexamethasone produced rapid and encouraging responses rates following lenalidomide–based therapy in patients with relapsed/refractory multiple myeloma, according to findings from the final analysis of the phase 2 DARIA trial. ....

International Staging System , Ixazomib Plus Daratumumab With Dexamethasone , Relapsed Refractory Multiple Myeloma , Eha 2023 , Hase 2 Daria Trial ,